Fragile X syndrome and fragile X-associated disorders
- PMID: 29259781
- PMCID: PMC5728189
- DOI: 10.12688/f1000research.11885.1
Fragile X syndrome and fragile X-associated disorders
Abstract
Fragile X syndrome (FXS) is caused by a full mutation on the FMR1 gene and a subsequent lack of FMRP, the protein product of FMR1. FMRP plays a key role in regulating the translation of many proteins involved in maintaining neuronal synaptic connections; its deficiency may result in a range of intellectual disabilities, social deficits, psychiatric problems, and dysmorphic physical features. A range of clinical involvement is also associated with the FMR1 premutation, including fragile X-associated tremor ataxia syndrome, fragile X-associated primary ovarian insufficiency, psychiatric problems, hypertension, migraines, and autoimmune problems. Over the past few years, there have been a number of advances in our knowledge of FXS and fragile X-associated disorders, and each of these advances offers significant clinical implications. Among these developments are a better understanding of the clinical impact of the phenomenon known as mosaicism, the revelation that various types of mutations can cause FXS, and improvements in treatment for FXS.
Keywords: FMR1 gene; copy number variants; point mutations; whole exome sequencing.
Conflict of interest statement
Competing interests: Randi Hagerman has received funding from Novartis, Neuren, Marinus, and Alcobra for carrying out treatment studies in patients with FXS and has also consulted with Roche, Novartis, Fulcrum and Zynerba regarding treatment studies in individuals with FXS.No competing interests were disclosed.No competing interests were disclosed.
Figures
References
-
- Saldarriaga W, et al. : Genetic Cluster of Fragile X Syndrome In A Colombian District. Journal of Medical Genetics. 2017, (in press). - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous
